Mathieu Castex, Ph.D
Mathieu Castex has been with Lallemand Animal Nutrition for close to a decade, committed since the beginning of his career to developing new applications for probiotics and yeast fractions applied to livestock and companion animals.
Mathieu is based at Lallemand Animal Nutrition’s headquarters near Toulouse, France, and is acting as head of the R&D department. He manages a multicultural team of microbiologists, physiologists and nutritionists conducting research projects aiming at developing and/or documenting the effects of microbial based feed additives on the performance and health of livestock. Particular efforts are dedicated to research aiming at revealing the biological mechanisms involved in the interactions between the animal (the host) and its microbiota, and how those interactions drive animal feed efficiency and health. Mathieu also manages the Lallemand Centers of Excellence, research platforms across Europe and North America dedicated to the understanding of microbial ecosystems , product development and investigation of their modes of action, and he is also in charge of a wide partnership network with research institutes across the world.
Mathieu holds a Master in animal sciences and a PhD in microbiology and physiology of nutrition applied to aquatic organisms from AgroParisTech (France). After a period at IFREMER (French Institute of Marine Science), he developed transversal experiences in terms of marketing, business development, bioprocessing and Research and Development. His major research interests are about the understanding of the complex interactions between the animal and its intestinal microbiota resulting in responses at the local (Gastrointestinal tract) and systemic levels.
Anne Chauder
Anne Chauder is the third generation at the head of a French independent family group of 350 employees, pioneer in animal health. In 2003, after studying Management, she chose to bring her skills to the family business. She became Executive Director in 2012 and then C.E.O in 2016 with aims to prepare the Dômes Pharma Group to address its third great evolution: digitalization and internationalization.
Vince Wacher
John F. Kokai-Kun, PhD
John F. Kokai-Kun, PhD is Vice President of Non-clinical Affairs for Synthetic Biologics, Inc. (Rockville, MD). He received his BS in Biochemistry from Juniata College in Huntingdon, PA and his PhD in Microbiology from the University of Pittsburgh, School of Medicine. He served as a post-doctoral researcher at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Kokai-Kun has 20 years of experience in the drug development industry and has held positions with several biotechnology and pharmaceutical companies where his research and development efforts have focused primarily on anti-bacterial drugs and vaccines. He has published more than 40 peer-reviewed publications relating to various aspects of drug development and microbial pathogenesis. Dr. Kokai-Kun is also an Adjunct Assistant Professor of Microbiology and Immunology at the Uniformed Services University and retired from the United States Army.
